Eric Feller
Chief Executive Officer at Targetome NV
Profile
Eric Feller currently works at Société de Gestion de Projets et de Valorisation SA, as Director from 2012 and Targetome NV, as Managing Director & Director from 2010.
Eric Feller active positions
Companies | Position | Start |
---|---|---|
Société de Gestion de Projets et de Valorisation SA
Société de Gestion de Projets et de Valorisation SA Miscellaneous Commercial ServicesCommercial Services Société de Gestion de Projets et de Valorisation SA operates as a holding company with interests in providing agricultural technology and equipment. It offers scientific technology services in the field of electricity transmission and monitoring of power lines. The company is headquartered in Gembloux, Belgium | Director/Board Member | 2012-05-28 |
Targetome NV
Targetome NV Pharmaceuticals: MajorHealth Technology Targetome SA operates is a biotech company which develops affinity-based targeted therapies against unmet medical needs with initial focus on pancreatic cancer and liver metastases. The firm develops antibody-drug conjugates. The company was founded by Edwin de Pauw and Vincent Castronovo in 2010 and is headquartered in Liege, Belgium. | Chief Executive Officer | 2010-07-04 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Société de Gestion de Projets et de Valorisation SA
Société de Gestion de Projets et de Valorisation SA Miscellaneous Commercial ServicesCommercial Services Société de Gestion de Projets et de Valorisation SA operates as a holding company with interests in providing agricultural technology and equipment. It offers scientific technology services in the field of electricity transmission and monitoring of power lines. The company is headquartered in Gembloux, Belgium | Commercial Services |
Targetome NV
Targetome NV Pharmaceuticals: MajorHealth Technology Targetome SA operates is a biotech company which develops affinity-based targeted therapies against unmet medical needs with initial focus on pancreatic cancer and liver metastases. The firm develops antibody-drug conjugates. The company was founded by Edwin de Pauw and Vincent Castronovo in 2010 and is headquartered in Liege, Belgium. | Health Technology |
- Stock Market
- Insiders
- Eric Feller